

Special Issue

Innovations in Drug Resistance: A Commemorative Issue in Honor of Prof. Salvador Luria

Message from the Guest Editors

Salvador Luria studied the development of bacterial resistance to phages, clarifying that mutations arise randomly and are selected by the presence of phages. The development of the Luria–Delbrück fluctuation test represents a brilliant moment in science, which opened up new landscapes in molecular genetics and led to Luria, Delbrück, and Hershey being awarded a Nobel Prize for their work. Indeed, it has been more than half a century since their study, but it is still relevant today, and Luria's pioneering work has provided elegant theoretical tools to face the drug resistance phenomenon, which continues to be a contemporary and challenging issue in microbiology and oncohematology. All manuscripts providing answers to the above questions are welcome in this Special Issue, which is aimed at celebrating the work of Salvador Luria, on what would have been the year of his 110th birthday. Original research articles describing innovative studies approaches to deal with drug resistance will be considered for publication. Systematic reviews and critical analyses reporting the most promising strategies to overcome the rise of drug-resistant agents will be welcome.

Guest Editors

Dr. Maria A. Bonifacio

Prof. Dr. Antonio Mazzocca

Prof. Dr. Anna Volpe

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/119725

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).